Authors:
Kuchel, GA
Tannenbaum, C
Greenspan, SL
Resnick, NM
Citation: Ga. Kuchel et al., Can variability in the hormonal status of elderly women assist in the decision to administer estrogens?, J WOMEN H G, 10(2), 2001, pp. 109-116
Authors:
Stoch, SA
Parker, RA
Chen, LP
Bubley, G
Ko, YJ
Vincelette, A
Greenspan, SL
Citation: Sa. Stoch et al., Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists, J CLIN END, 86(6), 2001, pp. 2787-2791
Authors:
Ferrari, SL
Garnero, P
Emond, S
Montgomery, H
Humphries, SE
Greenspan, SL
Citation: Sl. Ferrari et al., A functional polymorphic variant in the interleukin-6 gene prompter associated with low bone resorption in postmenopausal women, ARTH RHEUM, 44(1), 2001, pp. 196-201
Authors:
Stoch, SA
Wysong, E
Connolly, C
Parker, RA
Greenspan, SL
Citation: Sa. Stoch et al., Classification of osteoporosis and osteopenia in men is dependent on site-specific analysis, J CLIN DENS, 3(4), 2000, pp. 311-317
Authors:
Schnitzer, T
Bone, HG
Crepaldi, G
Adami, S
McClung, M
Kiel, D
Felsenberg, D
Recker, RR
Tonino, RP
Roux, C
Pinchera, A
Foldes, AJ
Greenspan, SL
Levine, MA
Emkey, R
Santora, AC
Kaur, A
Thompson, DE
Yates, J
Orloff, JJ
Citation: T. Schnitzer et al., Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis, AGING-CLIN, 12(1), 2000, pp. 1-12
Authors:
Marci, CD
Anderson, WB
Viechnicki, MB
Greenspan, SL
Citation: Cd. Marci et al., Bone mineral densitometry substantially influences health-related behaviors of postmenopausal women (vol 66, pg 113, 2000), CALCIF TIS, 67(5), 2000, pp. 425-425
Authors:
Rosen, HN
Moses, AC
Garber, J
Iloputaife, ID
Ross, DS
Lee, SL
Greenspan, SL
Citation: Hn. Rosen et al., Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy, CALCIF TIS, 66(2), 2000, pp. 100-103
Citation: Cd. Marci et al., Bone mineral densitometry substantially influences health-related behaviors of postmenopausal women, CALCIF TIS, 66(2), 2000, pp. 113-118
Citation: M. Horwitz et al., Editorial: Sequential parathyroid hormone/alendronate therapy for osteoporosis - Robbing Peter to pay Paul?, J CLIN END, 85(6), 2000, pp. 2127-2128
Authors:
Bone, HG
Greenspan, SL
McKeever, C
Bell, N
Davidson, M
Downs, RW
Emkey, R
Meunier, PJ
Miller, SS
Mulloy, AL
Recker, RR
Weiss, SR
Heyden, N
Musliner, T
Suryawanshi, S
Yates, AJ
Lombardi, A
Citation: Hg. Bone et al., Alendronate and estrogen effects in postmenopausal women with low bone mineral density, J CLIN END, 85(2), 2000, pp. 720-726
Citation: Sl. Greenspan et al., Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women, J CLIN END, 85(10), 2000, pp. 3537-3540
Authors:
Greenspan, SL
Harris, ST
Bone, H
Miller, PD
Orwoll, ES
Watts, NB
Rosen, CJ
Citation: Sl. Greenspan et al., Bisphosphonates: Safety and efficacy in the treatment and prevention of osteoporosis, AM FAM PHYS, 61(9), 2000, pp. 2731-2736
Authors:
Varney, LF
Parker, RA
Vincelette, A
Greenspan, SL
Citation: Lf. Varney et al., Classification of osteoporosis and osteopenia in postmenopausal women is dependent on site-specific analysis, J CLIN DENS, 2(3), 1999, pp. 275-283
Authors:
Miller, PD
Baram, DT
Bilezikian, JP
Greenspan, SL
Lindsay, R
Riggs, BL
Watts, NB
Citation: Pd. Miller et al., Practical clinical application of biochemical markers of bone turnover - Consensus of an Expert Panel, J CLIN DENS, 2(3), 1999, pp. 323-342
Citation: Ml. Bouxsein et al., Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women, OSTEOPOR IN, 10(6), 1999, pp. 505-509